GILD
GILEAD SCIENCES, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$143.72
−0.75%Price chart
Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8Sep 11
ValuationView details →
P/E (Fwd)
15.9x
EV/EBITDA
316.7x
Market Cap
$178.21B
MomentumView details →
1D Return
−0.75%
YTD Return
+17.40%
RSI (14)
51.3
ValuationView details →
P/E (Fwd)
15.9x
EV/EBITDA
316.7x
Market Cap
$178.21B
RSI (14)
51.3
MomentumView details →
1D Return
−0.75%
YTD Return
+17.40%
SummaryUpdated Jun 1, 2026
Gilead Sciences, Inc. (NASDAQ:GILD) is a leading biopharmaceutical company founded in 1987 and headquartered in Foster City, California. The company went public in 1992 and has established itself as a major player in the pharmaceutical industry, particularly known for its groundbreaking treatments in HIV/AIDS, hepatitis, and oncology. Gilead has built its reputation through innovative drug discovery and development, with a focus on addressing unmet medical needs in serious diseases. The company operates globally, serving patients in the United States, Europe, and international markets through its comprehensive portfolio of specialized medicines.
Similar companies
Latest newsMore news →
Merck's Keytruda was evaluated as monotherapy and in combination with Trodelvy in the Merck-sponsored Evoke-03/Keynote-D46 phase 3 trial in previously untreated PD-L1-high non-small cell lung cancer, with results presented at the 2026 World Conference on Lung Cancer.1d agoNICE issued draft guidance not recommending lenacapavir (Yeytuo), Gilead's twice-yearly HIV PrEP injection, for routine NHS use in England, citing cost-effectiveness above the acceptable range and uncertainties in clinical evidence and economic modelling.4d agoZambia received its first US-funded shipment of lenacapavir, an HIV prevention drug developed by Gilead Sciences, at the University Teaching Hospital in Lusaka on Wednesday.12d ago